Payment overview · 2025
General Payments
$900.01
50 reported records · 18 companies
Healthcare provider profile · identity verified
Guyle P Donham, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · COMANCHE, TX · NPI 1659386001
Verified facts
What the public records show
CMS Open Payments records show Guyle P Donham, D.O. received $900.01 in general payments during 2025 across 50 reported records.
Amgen Inc. accounted for 26.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Myrbetriq by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $239.02 | 26.6% | 15 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $135.52 | 15.1% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $88.47 | 9.8% | 5 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $52.33 | 5.8% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $51.96 | 5.8% | 3 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $43.21 | 4.8% | 2 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $38.97 | 4.3% | 2 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.88 | 3.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $30.16 | 3.4% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $28.61 | 3.2% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $27.06 | 3.0% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $23.79 | 2.6% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $23.56 | 2.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.91 | 2.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.95 | 2.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.10 | 1.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.35 | 1.7% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $14.16 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $900.01 | 50 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $167.96 | 7 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $135.52 | 8 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $88.47 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $88.47 | 5 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $52.33 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $51.96 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $50.04 | 3 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $43.21 | 2 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $38.97 | 2 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $31.88 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $30.16 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $30.16 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $28.61 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $27.06 | 1 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $23.79 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $23.56 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $21.02 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.91 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $19.76 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.95 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.10 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.35 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.35 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $14.16 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $14.16 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 110 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 125 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 111 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 20 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
35 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
157 | 30 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
110 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
113 | 110 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
20 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
110 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
125 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
65 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
111 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 619 | 110 |
| Atorvastatin Calcium | Atorvastatin Calcium | 609 | 139 |
| Pantoprazole Sodium | Pantoprazole Sodium | 606 | 140 |
| Losartan Potassium | Losartan Potassium | 544 | 120 |
| Furosemide | Furosemide | 482 | 101 |
| Gabapentin | Gabapentin | 420 | 88 |
| Amlodipine Besylate | Amlodipine Besylate | 390 | 92 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 349 | 86 |
| Tizanidine Hcl | Tizanidine Hcl | 347 | 88 |
| Sertraline Hcl | Sertraline Hcl | 340 | 70 |
| Lisinopril | Lisinopril | 336 | 86 |
| Metoprolol Succinate | Metoprolol Succinate | 317 | 85 |
| Montelukast Sodium | Montelukast Sodium | 315 | 78 |
| Potassium Chloride | Potassium Chloride | 310 | 74 |
| Tamsulosin Hcl | Tamsulosin Hcl | 298 | 84 |
| Eliquis | Apixaban | 278 | 40 |
| Donepezil Hcl | Donepezil Hcl | 271 | 45 |
| Tramadol Hcl | Tramadol Hcl | 246 | 63 |
| Allopurinol | Allopurinol | 216 | 43 |
| Meloxicam | Meloxicam | 209 | 51 |
| Celecoxib | Celecoxib | 208 | 59 |
| Memantine Hcl | Memantine Hcl | 207 | 40 |
| Farxiga | Dapagliflozin Propanediol | 206 | 43 |
| Omeprazole | Omeprazole | 200 | 48 |
| Metformin Hcl | Metformin Hcl | 199 | 44 |
| Carvedilol | Carvedilol | 183 | 44 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 182 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 180 | 45 |
| Alprazolam | Alprazolam | 165 | 33 |
| Myrbetriq | Mirabegron | 157 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 156 | 53 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 153 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 145 | 39 |
| Lorazepam | Lorazepam | 143 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 143 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 133 | 43 |
| Pregabalin | Pregabalin | 133 | 32 |
| Spironolactone | Spironolactone | 133 | 35 |
| Mounjaro | Tirzepatide | 125 | 26 |
| Mirtazapine | Mirtazapine | 121 | 20 |
| Trazodone Hcl | Trazodone Hcl | 121 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 114 | 25 |
| Xarelto | Rivaroxaban | 114 | 17 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 113 | 110 |
| Ozempic | Semaglutide | 111 | 19 |
| Ezetimibe | Ezetimibe | 110 | 25 |
| Jardiance | Empagliflozin | 110 | 15 |
| Divalproex Sodium | Divalproex Sodium | 107 | 13 |
| Glipizide | Glipizide | 104 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 102 | 16 |
| Dutasteride | Dutasteride | 102 | 25 |
| Simvastatin | Simvastatin | 100 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 99 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 96 | 26 |
| Fenofibrate | Fenofibrate Nanocrystallized | 89 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 86 | 16 |
| Nystatin | Nystatin | 82 | 33 |
| Diazepam | Diazepam | 81 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 77 | 21 |
| Levofloxacin | Levofloxacin | 70 | 60 |
| Prednisone | Prednisone | 70 | 21 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 69 | 18 |
| Metformin Hcl Er | Metformin Hcl | 68 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 66 | 25 |
| Trulicity | Dulaglutide | 65 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 65 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 64 | suppressed |
| Topiramate | Topiramate | 64 | 12 |
| Famotidine | Famotidine | 62 | 14 |
| Primidone | Primidone | 62 | 11 |
| Aripiprazole | Aripiprazole | 61 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 60 | 21 |
| Glipizide Er | Glipizide | 59 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 59 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 58 | suppressed |
| Azithromycin | Azithromycin | 57 | 52 |
| Estradiol | Estradiol | 57 | 11 |
| Gemtesa | Vibegron | 55 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 54 | 24 |
| Finasteride | Finasteride | 52 | 15 |
| Clonazepam | Clonazepam | 51 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 51 | 12 |
| Baclofen | Baclofen | 50 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | suppressed |
| Ondansetron Odt | Ondansetron | 50 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 49 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 48 | 33 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 48 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 48 | 12 |
| Sucralfate | Sucralfate | 47 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 46 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 45 | 12 |
| Meclizine Hcl | Meclizine Hcl | 45 | 16 |
| Testosterone Cypionate | Testosterone Cypionate | 45 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 44 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 43 | 17 |
| Dexlansoprazole Dr | Dexlansoprazole | 43 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 42 | suppressed |
| Levetiracetam | Levetiracetam | 42 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 42 | 26 |
| Nitroglycerin | Nitroglycerin | 41 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 41 | suppressed |
| Synthroid | Levothyroxine Sodium | 41 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 29 |
| Diclofenac Sodium | Diclofenac Sodium | 40 | 25 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 40 | 27 |
| Glimepiride | Glimepiride | 40 | suppressed |
| Lansoprazole | Lansoprazole | 40 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 39 | 26 |
| Albuterol Sulfate | Albuterol Sulfate | 38 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 38 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Methocarbamol | Methocarbamol | 37 | 11 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 37 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | suppressed |
| Linzess | Linaclotide | 35 | 12 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 35 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 35 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 35 | suppressed |
| Belsomra | Suvorexant | 34 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 34 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 34 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 33 | suppressed |
| Eszopiclone | Eszopiclone | 33 | suppressed |
| Fluconazole | Fluconazole | 33 | 21 |
| Vascepa | Icosapent Ethyl | 33 | suppressed |
| Latanoprost | Latanoprost | 32 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Mirabegron Er | Mirabegron | 31 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Atenolol | Atenolol | 30 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 30 | suppressed |
| Nifedipine Er | Nifedipine | 30 | suppressed |
| Temazepam | Temazepam | 30 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 20 |
| Fentanyl | Fentanyl | 28 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 28 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 28 | suppressed |
| Amoxicillin | Amoxicillin | 27 | 21 |
| Armour Thyroid | Thyroid,pork | 27 | suppressed |
| Buprenorphine | Buprenorphine | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Lactulose | Lactulose | 26 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 26 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 26 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Metronidazole | Metronidazole | 25 | 19 |
| Phenytoin | Phenytoin | 25 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 24 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Hydrocortisone | Hydrocortisone | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Febuxostat | Febuxostat | 23 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 22 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 21 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Olanzapine | Olanzapine | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 20 | 15 |
| Budesonide | Budesonide | 19 | suppressed |
| Cilostazol | Cilostazol | 19 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 18 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 18 | 14 |
| Nystop | Nystatin | 18 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Mesalamine | Mesalamine | 17 | suppressed |
| Novolin R | Insulin Regular, Human | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Scopolamine | Scopolamine | 16 | suppressed |
| Amantadine | Amantadine Hcl | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Cefdinir | Cefdinir | 15 | 14 |
| Acyclovir | Acyclovir | 14 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | 11 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Alprazolam Er | Alprazolam | 13 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Pentoxifylline | Pentoxifylline | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $900.01 · 50 records | Amgen Inc. | Cologuard Collection Kit, EVENITY, FREESTYLE LIBRE, Fluad, Flucelvax, JARDIANCE, JOURNAVX, KRYSTEXXA, Kerendia, LEQVIO, MOUNJARO, OTEZLA, Ozempic, PURIFIED CORTROPHIN GEL, QULIPTA, Qelbree, REPATHA, REXULTI, Rybelsus, SHINGRIX, SKYCLARYS, UBRELVY, Veozah, YUPELRI, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error